In 1992 the group was spun out of government and took on the name BTG plc when it was publicly listed in ’95. Following a strategic review in 2005, BTG plc focused on life sciences and began investing in specialty pharmaceuticals, notably through the acquisition of Protherics, another listed UK company, and establishment of a commercial and medical infrastructure in the US.
For several years BTG plc focused on minimally invasive procedures growing out of advances in medical imaging technology. BTG invested in a portfolio of devices to treat patients with cancer, vascular disease, and emphysema. In 2019 BTG plc was acquired by Boston Scientific, a global medical technology leader. In 2021 Boston Scientific divested BTG Specialty Pharmaceuticals.
Today BTG Specialty Pharmaceuticals is part of SERB Specialty Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®. These products are sold primarily in the United States through internal sales, marketing, The company has best-in-class capabilities in polyclonal antibody development and manufacturing with facilities in Wales, Australia, and Utah.